Clinical Trials Sponsored by Alembic Pharmaceuticals Ltd.

Total 4470 results

Idorsia Pharmaceuticals Ltd.

Completed

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (REVERSE)

Aneurysmal Subarachnoid Hemorrhage

Finland, France, Switzerland
Idorsia Pharmaceuticals Ltd.

Terminated

Tezosentan in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, France, Switzerland
Idorsia Pharmaceuticals Ltd.

Terminated

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Heart Diseases | Hypertension, Pulmonary

United States, United Kingdom, France, Israel, Canada, Sweden, Austria, Serbia, India, Czechia, Germany, Italy, Poland, Slovakia
Neurim Pharmaceuticals Ltd.

Completed

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Primary Insomnia

United States
Neurim Pharmaceuticals Ltd.

Completed

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Sleep Disorder | Alzheimer's Disease

United States, United Kingdom, Israel
Neurim Pharmaceuticals Ltd.

Terminated

Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia

Levodopa-induced Dyskinesia

Israel
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

Healthy Subjects

Czechia
Orasis Pharmaceuticals Ltd.

Completed

Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia

Presbyopia

Israel
Orasis Pharmaceuticals Ltd.

Completed

Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

Presbyopia

Israel
Galmed Pharmaceuticals Ltd

Terminated

Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study

Gallstones

Israel
Meditor Pharmaceuticals Ltd.

Withdrawn

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

Hypotension | Cardiopulmonary Bypass

United States
Galmed Pharmaceuticals Ltd

Completed

Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers

Healthy Volunteers
Affinium Pharmaceuticals, Ltd

Completed

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

Cellulitis | Wound Infection | Skin and Subcutaneous Tissue Bacterial Infections | Cutaneous Abscess | Burn Infection

United States, Canada
BiondVax Pharmaceuticals ltd.

Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Influenza

Israel
Neurim Pharmaceuticals Ltd.

Completed

Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects

Postural Instability

France
Sauflon Pharmaceuticals Ltd

Completed

Clinical Study of Clariti Monthly Contact Lens

Myopia | Hyperopia

United Kingdom
Inflazyme Pharmaceuticals Ltd

Completed

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

Asthma

United States
Targia Pharmaceuticals Ltd.
SoluBest Ltd.

Unknown

Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers

Migraine
Clarity Pharmaceuticals Ltd

Recruiting

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT) (COMBAT)

Prostatic Neoplasms | Castration-Resistant

United States
Fochon Pharmaceuticals, Ltd.

Recruiting

Study of FCN-098 in Patients With Advanced Solid Tumor

Solid Tumor

China
Fochon Pharmaceuticals, Ltd.

Recruiting

A Study of FCN-338 in Patients With Chronic CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Idorsia Pharmaceuticals Ltd.

Enrolling by invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

Acute Myocardial Infarction

United States, Spain, Denmark, Canada, Norway, France, China, United Kingdom, Hungary, Switzerland, Germany, Netherlands, Israel, Finland, Belgium, Czechia, Lithuania, Serbia, Austria, Greece, Italy, Bulgaria, Estonia, Poland, Romania, Sl...
Idorsia Pharmaceuticals Ltd.

Completed

A Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia

Nocturia | Insomnia Disorder

Spain, United States, Germany
Faron Pharmaceuticals Ltd

Completed

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Cancer

Finland, United Kingdom, Netherlands, United States, France, Spain
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain
KalVista Pharmaceuticals, Ltd.

Terminated

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (KVD824-201)

Angioedema, Hereditary, Types I and II

United States, Czechia, Germany, Hungary, Italy, North Macedonia, United Kingdom, Australia, Bulgaria, Canada, France, New Zealand, Puerto Rico
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Binge-Eating Disorder

United States
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Healthy

Israel
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Healthy Subjects

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

Bioequivalence Study of Different Aprocitentan Tablet Formulations

Healthy Subjects

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Acute Myocardial Infarction

Switzerland, Israel, Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Healthy

Germany
Kiniksa Pharmaceuticals, Ltd.

Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

COVID

United States, Brazil, South Africa, Chile, Peru
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)

Fabry Disease

United States, Spain, Belgium, Australia, Austria, Canada, Germany, Ireland, Italy, Netherlands, Norway, Poland, Switzerland, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Healthy Subjects

Germany
Faron Pharmaceuticals Ltd

Withdrawn

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma (RENACOL)

Carcinoma, Renal Cell | Carcinoma Colon

Finland
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Australia, Canada, Denmark, Italy, Poland, Serbia, Spain, Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Korea, Republic of, Germany, Belgium, Bulgaria, Canada, Czechia, Finland, France, Hungary, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470

Healthy | Drug Drug Interaction

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Healthy

Portugal
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands

3

Subscribe